Review
Copyright ©The Author(s) 2024.
World J Gastroenterol. Aug 21, 2024; 30(31): 3654-3667
Published online Aug 21, 2024. doi: 10.3748/wjg.v30.i31.3654
Table 1 Preclinical studies involving B7 homolog 3-targeting agents in pancreatic cancer
Ref.
Agent/drug
Study models
Lutz et al[101]Fc-optimized mAb B7-H3-SDIEIn vitro PDAC model
Kasten et al[103]B7-H3-specific mAb 376.96 conjugated with 212PbPDAC in vitro and PDX models
Scribner et al[104] and Wittwer et al[105]MGC0181 (alone or combined with an anti-PD-1 agent)PC PDX and immunocompetent mouse models
Lutz et al[114]B7-H3xCD3 bsAb CC-3In vitro hepatic, gastric, and PDAC models
You et al[115]B7-H3x4-1BB2 bsAbIn vitro models of PC and other solid tumors
Table 2 Clinical studies involving B7 homolog 3-targeting agents in pancreatic cancer
Ref.
Agent/drug
Route of administration
Study participants
Status
NCT05293496, phase I[106]Vobramitamab duocarmazine1 in combination with lorigerlimab2IntravenousPatients with relapsed or refractory, unresectable, locally advanced, or metastatic solid tumors including PCRecruiting
NCT06330064, phase II[110]I-DXD3IntravenousPatients with recurrent or metastatic solid tumors, including PDACRecruiting
NCT02628535, phase I[113]Orlotamab4IntravenousPatients with unresectable or metastatic B7-H3-expressing neoplasms including PCTerminated
NCT05143151, phase I/phase II[117]CD276 CAR T cellsIntravenousAdult patients with refractory PCRecruiting
NCT06158139, phase I[118]Ic9-CAR.B7-H3 T cellsIntravenousAdult patients with refractory PDACNot yet recruiting